Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Coloplast shares surge as Danish medtech group delivers strong Q1

(Sharecast News) - Danish medical device group Coloplast saw shares surge over 8% in Copenhagen on Friday after the company delivered high single-digit growth across all areas of the business in the first quarter. Organic revenues were up 8% in the three months to 31 December, in line with Coloplast's full-year growth rate guidance, while earnings before interest and tax gained 3% to DKK 1.82bn.

Organic revenues in the Ostomy Care business rose 8%, Continence Care increased 8%, Voice and Respiratory Care was up 7%, Advanced Wound Care rose 9% while Interventional Urology improved by 5%.

Meanwhile, biologics woundcare firm Kerecis was acquired last August for DKK 8.9bn ($1.3bn) made a strong start to the new financila year and saw underlying growth in the first quarter of 35% on the back of market share gains.

The company said it continues to expect 8% organic growth over the full year to 30 October 2024, but that reported growth in Danish krone has been trimmed to 11% from 12% previously due to negative currency movements. Meanwhile, Kerecis is estimated to account for four percentage points to group revenue growth over the full year.

Chief executive Kristian Villumsen said the company delivered a "good start", saying: "I want to highlight a strong first quarter in our Chronic Care business, which delivered broad-based growth, as well as a good start to the year for our newest member of the Coloplast family, Kerecis."

Villumsen continued: "We have now kicked off a year of product launches that will help drive our future growth. This quarter, we are launching Biatain Silicone Fit for pressure injury prevention and wound management in the US, as well as Peristeen® Light for people with bowel disorders in Europe. I believe both products will make a significant difference to people living with intimate healthcare needs."

The stock was up 8.2% at kr 878.8 by 1223 CET.

Share this article

Related Sharecast Articles

JPMorgan Chase Q1 profits jump
(Sharecast News) - JPMorgan Chase reported a 6% jump in first-quarter profit on Friday as net interest income rose.
R&Q Insurance shares plummet on weak guidance
(Sharecast News) - R&Q Insurance, the AIM-listed non-life insurer, lost almost half of its market value on Friday after announcing it would report a "significant pre-tax loss" for last year.
SigmaRoc delivers 'solid' Q1 performance
(Sharecast News) - Limestone group SigmaRoc said on Friday that it had delivered a "solid Q1 performance", with underlying earnings in line with management expectations.
Samsung in line to secure $6bn in US government grants
(Sharecast News) - Electronics giant Samsung will unveil a $44.0bn White House programme aimed at bringing semiconductor production back to America as soon as next week, with the memory chip maker in line to secure up to $6.0bn in government grants.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.